A phase I trial of combination CAR-NK92MI immunotherapy by dual targeting MUC-1 and PD-L1 for patients with relapsed or refractory solid tumors: focus on non-small cell lung cancer

医学 耐火材料(行星科学) 嵌合抗原受体 内科学 免疫疗法 肺癌 肿瘤科 不利影响 细胞因子释放综合征 临床试验 进行性疾病 靶向治疗 细胞疗法 临床研究阶段 抗原 癌症 免疫学 化疗 疾病 肺 细胞 胃肠病学 癌症研究 癌症免疫疗法 细胞因子
作者
Jing Lin,Wenchao Xu,Leiming Xia,Congshu Zhang,Lei Ge,Junfeng Gao,Jian Bao,Xu Yang,Xiang Sun,Hongxia Li,Yi Wang
出处
期刊:BMC Pulmonary Medicine [BioMed Central]
卷期号:25 (1): 482-482 被引量:5
标识
DOI:10.1186/s12890-025-03944-y
摘要

BACKGROUND: NK92MI cells are well-defined natural killer (NK) cell lines for tumor immunotherapy. In this study, we investigated a combination therapy of MUC-1 and PD-L1 targeted chimeric antigen receptor NK92MI (CAR-NK92MI) cells for advanced non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: From 2016 to 2018, 7 patients with relapsed or refractory NSCLC were included in this clinical trial (ClinicalTrials.gov number, NCT02839954.Registered in 21/07/2016.). 1:1 mixed MUC-1 and PD-L1 CAR-NK92MI cells were infused, and the dosage was set at 1 × 108 to 2 × 109 CAR-NK92MI cells once. The infusion times were ranged from 3 to 37, and the median time were 22. All patients completed CAR-NK92MI cells infusion within 1 year unless intolerable toxicities appeared or disease progression (PD) occurred. RESULTS: All 7 patients were well-tolerated in the treatment. No cytokine release syndrome (CRS) and serious adverse events related to CAR-NK92MI treatment were observed. 3/7 patients achieved stable disease within more than 23 months. The median progression-free survival (PFS) was 12 months (2 to 60months) from the initial treatment, and the median overall survival (OS) was 19 months (3 to 60 months). CONCLUSION: Our results demonstrated that the combined MUC-1 and PD-L1 targeted CAR-NK92MI cell therapy is safe and efficient approach for relapsed and refractory NSCLC patients with metastasis. TRIAL REGISTRATION: Our study was registered in ClinicalTrials.gov ( https://classic.clinicaltrials.gov/ ) (NCT02839954) in 21/07/2016.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
没有ID完成签到,获得积分10
刚刚
Lucas的应助被HouKk采纳,获得10
1秒前
橘络完成签到 ,获得积分10
1秒前
张丁发布了新的文献求助10
1秒前
我是老大的应助被123采纳,获得10
1秒前
2秒前
灵巧阑香发布了新的文献求助10
2秒前
DW的应助被68zx采纳,获得10
2秒前
虚心的不二完成签到 ,获得积分10
3秒前
Hello的应助被勤奋一一采纳,获得10
3秒前
无极微光的应助被邪恶螺蛳粉采纳,获得20
4秒前
4秒前
科研通AI2S的应助被JeanetteJin采纳,获得10
4秒前
4秒前
山河西瓜完成签到,获得积分10
4秒前
5秒前
DFourC完成签到 ,获得积分10
5秒前
6秒前
6秒前
7秒前
7秒前
平怀晨发布了新的文献求助10
7秒前
9秒前
9秒前
9秒前
王佳佳发布了新的文献求助10
9秒前
情怀的应助被themoomofeye采纳,获得10
10秒前
10秒前
来都来了完成签到,获得积分10
10秒前
Adrian完成签到,获得积分10
10秒前
yxy发布了新的文献求助10
11秒前
11秒前
Hello的应助被zhuzhenghua采纳,获得10
11秒前
11秒前
11秒前
12秒前
12秒前
lld发布了新的文献求助10
12秒前
12秒前
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Markov Decision Processes and Reinforcement Learning 700
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8170973
求助须知:如何正确求助?哪些是违规求助? 9563727
关于积分的说明 21771951
捐赠科研通 7762452
什么是DOI,文献DOI怎么找? 3430786
关于科研通互助平台的介绍 2554629
邀请新用户注册赠送积分活动 2475637